カテゴリ： Infiniti Research TechNavio, 世界, 医療/バイオ

ヒトパピローマウイルス（HPV）治療のグローバル市場2023～2027：非経口、局所

■ 英語タイトル：Global Human Papillomavirus (HPV) Therapeutics Market 2023-2027

調査会社Technavio社が発行したリサーチレポート（データ管理コード：IRTNTR72565-23）■ 発行会社/調査会社：Technavio
■ 商品コード：IRTNTR72565-23
■ 発行日：2023年3月15日
■ 調査対象地域：北米、ヨーロッパ、アジア、その他地域
■ 産業分野：医薬品
■ ページ数：約120
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,500 ⇒換算￥380,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD4,000 ⇒換算￥608,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ヒトパピローマウイルス（HPV）治療のグローバル市場2023～2027：非経口、局所]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Technavio社の本報告書では、世界のヒトパピローマウイルス（HPV）治療市場規模が2022年から2027年の間に953.3百万ドルまで上昇すると推定しており、予測期間中にCAGR 5.15%成長する見込みです。本書ではヒトパピローマウイルス（HPV）治療の世界市場を調査し、エグゼクティブサマリー、市場状況、市場規模予測、過去の市場規模、ファイブフォース分析、投与経路別（非経口、局所）分析、疾患別（子宮頸がん、肛門がん、外陰がん＆膣がん、その他）分析、地域別（北米、ヨーロッパ、アジア、その他地域、アメリカ、ドイツ、カナダ、中国、ブラジル）分析、顧客状況、推進要因・課題・動向、企業状況、企業分析などの内容をまとめました。なお、2A Pharma ApS, AbbVie Inc., Bavarian Nordic AS, BioVaxys Technology Corp., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ISA Pharmaceuticals BV, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Xiamen Innovax Biotech Co. Ltd., Merck and Co. Inc., Bausch Health Co. Inc., Inovio Pharmaceuticals Inc.などの関連企業情報が収録されています。
・エグゼクティブサマリー
・市場状況
・市場規模予測
・過去の市場規模
・ファイブフォース分析
・世界のヒトパピローマウイルス（HPV）治療市場規模：投与経路別
- 非経口治療の市場規模
- 局所治療の市場規模
・世界のヒトパピローマウイルス（HPV）治療市場規模：疾患別
- 子宮頸がんにおける市場規模
- 肛門がんにおける市場規模
- 外陰がん＆膣がんにおける市場規模
- その他疾患における市場規模
・顧客状況
・世界のヒトパピローマウイルス（HPV）治療市場規模：地域別
- 北米のヒトパピローマウイルス（HPV）治療市場規模
- ヨーロッパのヒトパピローマウイルス（HPV）治療市場規模
- アジアのヒトパピローマウイルス（HPV）治療市場規模
- その他地域のヒトパピローマウイルス（HPV）治療市場規模
- アメリカのヒトパピローマウイルス（HPV）治療市場規模
- ドイツのヒトパピローマウイルス（HPV）治療市場規模
- カナダのヒトパピローマウイルス（HPV）治療市場規模
- 中国のヒトパピローマウイルス（HPV）治療市場規模
- ブラジルのヒトパピローマウイルス（HPV）治療市場規模
・推進要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益・価格・競争・プロモーションなどの主なパラメーターを分析することにより、複数の情報源からのデータを調査・統合・統括することで、ヒトパピローマウイルス（HPV）治療市場の詳細な全体像を提示します。主要産業のインフルエンサーを特定することにより、多様な市場の側面を提示します。これらのデータは包括的​​且つ信頼性が高く、一次・二次の広範な調査の結果です。Technavio社の市場調査資料は、正確なヒトパピローマウイルス（HPV）治療市場の成長を予測するため、定性的・定量的調査により徹底的な競合状況、詳細に及ぶベンダー選定＆分析を提供します。

ヒトパピローマウイルス（HPV）治療の世界市場 2023-2027

Technavio社は、ヒトパピローマウイルス（HPV）治療市場をモニターしており、2022年から2027年にかけて953.3百万ドルの成長が予測され、予測期間中のCAGRは5.15%で加速すると予測しています。当レポートでは、ヒトパピローマウイルス（HPV）治療市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、さらに約25のベンダーを網羅したベンダー分析などを提供しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場を牽引するのは、ワクチンの登場、HPV用経口ワクチンの開発、旺盛な疾患進行です。

Technavioのヒトパピローマウイルス（HPV）治療市場は以下のように区分されます：

・投与経路別：
– 非経口剤
– 局所投与

・疾患別：
– 子宮頸がん
– 肛門がん
– 外陰・腟がん
– その他

・地域別：
– 北米
– ヨーロッパ
– アジア
– その他の地域（ROW）

本調査では、今後数年間のヒトパピローマウイルス（HPV）治療市場の成長を促進する主な理由の一つとして、起立性低血圧治療のための新薬の研究開発を挙げています。また、治療における併用療法や、フルドロコルチゾンの適応外第一選択薬としての採用は、市場の大きな需要につながるでしょう。

Technavio社は、複数の情報源からのデータを調査、統合、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

当レポートでは、ヒトパピローマウイルス（HPV）治療市場について以下の分野をカバーしています：
– ヒトパピローマウイルス（HPV）治療市場のサイジング
– ヒトパピローマウイルス（HPV）治療市場予測
– ヒトパピローマウイルス（HPV）治療市場の産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、2A Pharma ApS, AbbVie Inc., Bavarian Nordic AS, BioVaxys Technology Corp., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ISA Pharmaceuticals BV, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Xiamen Innovax Biotech Co. Ltd., Merck and Co. Inc., Bausch Health Co. Inc., and Inovio Pharmaceuticals Incなどの企業情報が含まれています。また、ヒトパピローマウイルス（HPV）治療市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavio社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Indication
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global Human Papillomavirus (HPV) therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global Human Papillomavirus (HPV) therapeutics market 2017 – 2021 ($ million)
o 4.2 route of administration Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – route of administration Segment 2017 – 2021 ($ million)
o 4.3 Indication Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Indication Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Route of Administration – Market share 2022-2027 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Parenteral – Market size and forecast 2022-2027
o Exhibit 34: Chart on Parenteral – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Parenteral – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Parenteral – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Parenteral – Year-over-year growth 2022-2027 (%)
o 6.4 Topical – Market size and forecast 2022-2027
o Exhibit 38: Chart on Topical – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Topical – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Topical – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Topical – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 42: Market opportunity by Route of Administration ($ million)
o Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Indication
o 7.1 Market segments
o Exhibit 44: Chart on Indication – Market share 2022-2027 (%)
o Exhibit 45: Data Table on Indication – Market share 2022-2027 (%)
o 7.2 Comparison by Indication
o Exhibit 46: Chart on Comparison by Indication
o Exhibit 47: Data Table on Comparison by Indication
o 7.3 Cervical cancer – Market size and forecast 2022-2027
o Exhibit 48: Chart on Cervical cancer – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Data Table on Cervical cancer – Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Chart on Cervical cancer – Year-over-year growth 2022-2027 (%)
o Exhibit 51: Data Table on Cervical cancer – Year-over-year growth 2022-2027 (%)
o 7.4 Anal cancer – Market size and forecast 2022-2027
o Exhibit 52: Chart on Anal cancer – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Anal cancer – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Anal cancer – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Anal cancer – Year-over-year growth 2022-2027 (%)
o 7.5 Vulvar and vaginal cancer – Market size and forecast 2022-2027
o Exhibit 56: Chart on Vulvar and vaginal cancer – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Vulvar and vaginal cancer – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Vulvar and vaginal cancer – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Vulvar and vaginal cancer – Year-over-year growth 2022-2027 (%)
o 7.6 Others – Market size and forecast 2022-2027
o Exhibit 60: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Indication
o Exhibit 64: Market opportunity by Indication ($ million)
o Exhibit 65: Data Table on Market opportunity by Indication ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share by geography 2022-2027 (%)
o Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 71: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 87: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Germany – Market size and forecast 2022-2027
o Exhibit 91: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.9 Canada – Market size and forecast 2022-2027
o Exhibit 95: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.10 China – Market size and forecast 2022-2027
o Exhibit 99: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.11 Brazil – Market size and forecast 2022-2027
o Exhibit 103: Chart on Brazil – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on Brazil – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on Brazil – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on Brazil – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 107: Market opportunity by geography ($ million)
o Exhibit 108: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 2A Pharma ApS
o Exhibit 115: 2A Pharma ApS – Overview
o Exhibit 116: 2A Pharma ApS – Product / Service
o Exhibit 117: 2A Pharma ApS – Key offerings
o 12.4 AbbVie Inc.
o Exhibit 118: AbbVie Inc. – Overview
o Exhibit 119: AbbVie Inc. – Product / Service
o Exhibit 120: AbbVie Inc. – Key news
o Exhibit 121: AbbVie Inc. – Key offerings
o 12.5 Bausch Health Co. Inc.
o Exhibit 122: Bausch Health Co. Inc. – Overview
o Exhibit 123: Bausch Health Co. Inc. – Business segments
o Exhibit 124: Bausch Health Co. Inc. – Key news
o Exhibit 125: Bausch Health Co. Inc. – Key offerings
o Exhibit 126: Bausch Health Co. Inc. – Segment focus
o 12.6 Bavarian Nordic AS
o Exhibit 127: Bavarian Nordic AS – Overview
o Exhibit 128: Bavarian Nordic AS – Product / Service
o Exhibit 129: Bavarian Nordic AS – Key offerings
o 12.7 BioVaxys Technology Corp.
o Exhibit 130: BioVaxys Technology Corp. – Overview
o Exhibit 131: BioVaxys Technology Corp. – Product / Service
o Exhibit 132: BioVaxys Technology Corp. – Key offerings
o 12.8 F. Hoffmann La Roche Ltd.
o Exhibit 133: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 134: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 135: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 136: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 137: F. Hoffmann La Roche Ltd. – Segment focus
o 12.9 GlaxoSmithKline Plc
o Exhibit 138: GlaxoSmithKline Plc – Overview
o Exhibit 139: GlaxoSmithKline Plc – Business segments
o Exhibit 140: GlaxoSmithKline Plc – Key offerings
o Exhibit 141: GlaxoSmithKline Plc – Segment focus
o 12.10 Inovio Pharmaceuticals Inc.
o Exhibit 142: Inovio Pharmaceuticals Inc. – Overview
o Exhibit 143: Inovio Pharmaceuticals Inc. – Product / Service
o Exhibit 144: Inovio Pharmaceuticals Inc. – Key news
o Exhibit 145: Inovio Pharmaceuticals Inc. – Key offerings
o 12.11 ISA Pharmaceuticals BV
o Exhibit 146: ISA Pharmaceuticals BV – Overview
o Exhibit 147: ISA Pharmaceuticals BV – Product / Service
o Exhibit 148: ISA Pharmaceuticals BV – Key offerings
o 12.12 Merck and Co. Inc.
o Exhibit 149: Merck and Co. Inc. – Overview
o Exhibit 150: Merck and Co. Inc. – Business segments
o Exhibit 151: Merck and Co. Inc. – Key news
o Exhibit 152: Merck and Co. Inc. – Key offerings
o Exhibit 153: Merck and Co. Inc. – Segment focus
o 12.13 Serum Institute of India Pvt. Ltd.
o Exhibit 154: Serum Institute of India Pvt. Ltd. – Overview
o Exhibit 155: Serum Institute of India Pvt. Ltd. – Product / Service
o Exhibit 156: Serum Institute of India Pvt. Ltd. – Key offerings
o 12.14 Walvax Biotechnology Co. Ltd.
o Exhibit 157: Walvax Biotechnology Co. Ltd. – Overview
o Exhibit 158: Walvax Biotechnology Co. Ltd. – Product / Service
o Exhibit 159: Walvax Biotechnology Co. Ltd. – Key offerings
o 12.15 Xiamen Innovax Biotech Co. Ltd.
o Exhibit 160: Xiamen Innovax Biotech Co. Ltd. – Overview
o Exhibit 161: Xiamen Innovax Biotech Co. Ltd. – Product / Service
o Exhibit 162: Xiamen Innovax Biotech Co. Ltd. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 163: Inclusions checklist
o Exhibit 164: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 165: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 166: Research methodology
o Exhibit 167: Validation techniques employed for market sizing
o Exhibit 168: Information sources
o 13.5 List of abbreviations
o Exhibit 169: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary – Chart on Market Segmentation by Indication
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global Human Papillomavirus (HPV) therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – route of administration Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Indication Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Route of Administration – Market share 2022-2027 (%)
Exhibits31: Data Table on Route of Administration – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Parenteral – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Parenteral – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Parenteral – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Parenteral – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Topical – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Topical – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Topical – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Topical – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Route of Administration ($ million)
Exhibits43: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits44: Chart on Indication – Market share 2022-2027 (%)
Exhibits45: Data Table on Indication – Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Indication
Exhibits47: Data Table on Comparison by Indication
Exhibits48: Chart on Cervical cancer – Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Cervical cancer – Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Cervical cancer – Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Cervical cancer – Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Anal cancer – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Anal cancer – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Anal cancer – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Anal cancer – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Vulvar and vaginal cancer – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Vulvar and vaginal cancer – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Vulvar and vaginal cancer – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Vulvar and vaginal cancer – Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits64: Market opportunity by Indication ($ million)
Exhibits65: Data Table on Market opportunity by Indication ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share by geography 2022-2027 (%)
Exhibits68: Data Table on Market share by geography 2022-2027 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on Brazil – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on Brazil – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on Brazil – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on Brazil – Year-over-year growth 2022-2027 (%)
Exhibits107: Market opportunity by geography ($ million)
Exhibits108: Data Tables on Market opportunity by geography ($ million)
Exhibits109: Impact of drivers and challenges in 2022 and 2027
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: 2A Pharma ApS – Overview
Exhibits116: 2A Pharma ApS – Product / Service
Exhibits117: 2A Pharma ApS – Key offerings
Exhibits118: AbbVie Inc. – Overview
Exhibits119: AbbVie Inc. – Product / Service
Exhibits120: AbbVie Inc. – Key news
Exhibits121: AbbVie Inc. – Key offerings
Exhibits122: Bausch Health Co. Inc. – Overview
Exhibits123: Bausch Health Co. Inc. – Business segments
Exhibits124: Bausch Health Co. Inc. – Key news
Exhibits125: Bausch Health Co. Inc. – Key offerings
Exhibits126: Bausch Health Co. Inc. – Segment focus
Exhibits127: Bavarian Nordic AS – Overview
Exhibits128: Bavarian Nordic AS – Product / Service
Exhibits129: Bavarian Nordic AS – Key offerings
Exhibits130: BioVaxys Technology Corp. – Overview
Exhibits131: BioVaxys Technology Corp. – Product / Service
Exhibits132: BioVaxys Technology Corp. – Key offerings
Exhibits133: F. Hoffmann La Roche Ltd. – Overview
Exhibits134: F. Hoffmann La Roche Ltd. – Business segments
Exhibits135: F. Hoffmann La Roche Ltd. – Key news
Exhibits136: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits137: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits138: GlaxoSmithKline Plc – Overview
Exhibits139: GlaxoSmithKline Plc – Business segments
Exhibits140: GlaxoSmithKline Plc – Key offerings
Exhibits141: GlaxoSmithKline Plc – Segment focus
Exhibits142: Inovio Pharmaceuticals Inc. – Overview
Exhibits143: Inovio Pharmaceuticals Inc. – Product / Service
Exhibits144: Inovio Pharmaceuticals Inc. – Key news
Exhibits145: Inovio Pharmaceuticals Inc. – Key offerings
Exhibits146: ISA Pharmaceuticals BV – Overview
Exhibits147: ISA Pharmaceuticals BV – Product / Service
Exhibits148: ISA Pharmaceuticals BV – Key offerings
Exhibits149: Merck and Co. Inc. – Overview
Exhibits150: Merck and Co. Inc. – Business segments
Exhibits151: Merck and Co. Inc. – Key news
Exhibits152: Merck and Co. Inc. – Key offerings
Exhibits153: Merck and Co. Inc. – Segment focus
Exhibits154: Serum Institute of India Pvt. Ltd. – Overview
Exhibits155: Serum Institute of India Pvt. Ltd. – Product / Service
Exhibits156: Serum Institute of India Pvt. Ltd. – Key offerings
Exhibits157: Walvax Biotechnology Co. Ltd. – Overview
Exhibits158: Walvax Biotechnology Co. Ltd. – Product / Service
Exhibits159: Walvax Biotechnology Co. Ltd. – Key offerings
Exhibits160: Xiamen Innovax Biotech Co. Ltd. – Overview
Exhibits161: Xiamen Innovax Biotech Co. Ltd. – Product / Service
Exhibits162: Xiamen Innovax Biotech Co. Ltd. – Key offerings
Exhibits163: Inclusions checklist
Exhibits164: Exclusions checklist
Exhibits165: Currency conversion rates for US$
Exhibits166: Research methodology
Exhibits167: Validation techniques employed for market sizing
Exhibits168: Information sources
Exhibits169: List of abbreviations



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • エクソソーム診断＆治療のグローバル市場2023～2027：研究&学術機関、製薬＆バイオ企業、商業
  • 遺伝性血管性浮腫（HAE）治療のグローバル市場2023-2027：病院薬局、小売薬局、電子商取引
  • 尿素サイクル障害（UCD）治療のグローバル市場2023-2027：フェニル酪酸グリセロール、フェニル酪酸ナトリウム、アミノ酸サプリメント、安息香酸ナトリウム、その他
  • ヒトパピローマウイルス（HPV）アッセイキットの世界市場2023-2029：15以下、15-20、20以上
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(IRTNTR72565-23 )"ヒトパピローマウイルス（HPV）治療のグローバル市場2023～2027：非経口、局所" (英文：Global Human Papillomavirus (HPV) Therapeutics Market 2023-2027)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。